Chlamydia trachomatis (CT)

With 127 million new infections per year, Chlamydia trachomatis (CT) is one of the most common sexually transmitted infections (STIs).¹

The majority of CT cases do not present with symptoms, making management of these bacterial infections a challenge. Undiagnosed and untreated, CT may result in complications that affect the urethra, cervix, uterus, and prostate. CT is also a known cause of infertility in women.²

Chlamydia is generally curable with existing, effective single-dose regimens of antibiotics, but has shown early signs of resistance.³ Diagnostic testing is an important strategic tool to help mitigate the impact of the disease, and stave off the potential consequences from a drug-resistant form of the bacteria.

Roche introduced the first-ever FDA-cleared PCR test for CT in 1993. Since then, the assay has been continually developed, along with the respective analytical solutions—gaining significant advances in automation and accuracy, plus the ability to test for multiple sexually transmitted infections on one platform using a single sample.

This enhanced diagnostic sensitivity, improved flexibility, and reduced human error due to automation will enable technicians to work more efficiently while empowering clinicians to make CT testing a more routine part of patient care.